From US To EU: Young Biotechs Going It Alone
There Are Several Barriers For A US Biotech To Overcome For A Successful Launch In Europe
Executive Summary
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.
You may also be interested in...
Welcome To Alexion 2.0
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.
Sanofi's Libtayo Lands In EU With Skin Cancer Nod
Nine months after the US approval, the EU has followed suit and given a conditional approval for Sanofi and Regeneron’s IO Libtayo for a, so far, untreatable skin cancer.
Sarepta Shares Bounce As Pfizer’s DMD Gene Therapy Sparks Safety Concerns
Pfizer is forging ahead with a Phase III trial for its DMD therapy, even though Phase Ib data raised safety worries. Gene therapy rival Sarepta’s shares were up by 17% on the news.